Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Next-generation high content screening system launched by PerkinElmer

PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, has announced the launch of the Opera Phenix™, a next-generation, confocal, high-content screening system that will enable scientists to perform the most challenging applications with greater speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatments.

23 Jan 2014

Function of stem cells in blood-forming system is regulated by estrogen, says study

Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system — which is similar in both sexes — also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal.

23 Jan 2014

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

New research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

23 Jan 2014

Mutation in bone cells may cause acute myeloid leukemia: Study

Acute myeloid leukemia is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells.

21 Jan 2014

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

The Damon Runyon Cancer Research Foundation announced that six scientists with novel approaches to fighting cancer have been named 2014 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

21 Jan 2014

Childhood brain cancer (ETMR/ETANTR): an interview with Dr. Nada Jabado, Department of Pediatrics at McGill University

Embryonal tumours with multilayered rosettes (ETMR) are rare, deadly brain tumours that affect mainly children below the age of 4 years. There are 300 cases reported but probably there are many more as this tumour is often misdiagnosed.

21 Jan 2014

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest.

From Fluxion Biosciences 21 Jan 2014

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

21 Jan 2014

Splicing factor SRSF6 promotes hyperplasia of sensitized skin

Normally, tissue injury triggers a mechanism in cells that tries to repair damaged tissue and restore the skin to a normal, or homeostatic state. Errors in this process can give rise to various problems, such as chronic inflammation, which is a known cause of certain cancers.

21 Jan 2014

Study shows interactions between skin stem cells and cells responsible for renewal of skin

The human body is daily exposed to external assaults such as bacteria, ultraviolet light or chemical agents. Skin, the largest organ of the body, is the first line of defense against these agents.

20 Jan 2014

Axxam, Cellectis bioresearch partner to offer cell-based assays to Life Science industry

Axxam (Milan), a leading provider of discovery services including assay development for high-throughput screening, and Cellectis bioresearch (Paris), the cell engineering expert, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies.

19 Jan 2014

BioTime subsidiary releases version 1.5 of LifeMap Discovery

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of LifeMap Discovery version 1.5. LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology.

18 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Single stem cell injection after meniscus knee surgery may provide pain relief, aid in meniscus regrowth

A single stem cell injection following meniscus knee surgery may provide pain relief and aid in meniscus regrowth, according to a novel study appearing in the January issue of the Journal of Bone and Joint Surgery (JBJS).

17 Jan 2014

RNA sequencing unlocks bipolar secrets

An RNA sequencing study of patients with bipolar disorder has shown altered expression of genes and transcripts, including those involved in neuroplasticity and circadian rhythms.

16 Jan 2014

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

Cord Blood Registry, the world's largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child's stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss.

16 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients.

16 Jan 2014

New stem cell study explains how breast cancer spreads

Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.

15 Jan 2014

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications.

15 Jan 2014

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States.

15 Jan 2014

Stem Cells News and Research

Further Reading

Next-generation high content screening system launched by PerkinElmer

Function of stem cells in blood-forming system is regulated by estrogen, says study

Number of cancer stem cells in tumor might inaccurately estimate tumor's recurrence or progression

Mutation in bone cells may cause acute myeloid leukemia: Study

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

Childhood brain cancer (ETMR/ETANTR): an interview with Dr. Nada Jabado, Department of Pediatrics at McGill University

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

Splicing factor SRSF6 promotes hyperplasia of sensitized skin

Study shows interactions between skin stem cells and cells responsible for renewal of skin

Axxam, Cellectis bioresearch partner to offer cell-based assays to Life Science industry

BioTime subsidiary releases version 1.5 of LifeMap Discovery

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Single stem cell injection after meniscus knee surgery may provide pain relief, aid in meniscus regrowth

RNA sequencing unlocks bipolar secrets

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

New stem cell study explains how breast cancer spreads

Cedars-Sinai investigators identify new molecular abnormalities in diabetic cornea

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo